Skip to main content

Table 1 Patients' characteristics at the time of ESTA

From: Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping

No. of patients with available ESTA result

51

ESTA results, n (%)

CCR5-tropic

31 (61%)

  

Dual/Mixed-tropic

12 (23%)

  

CXCR4-tropic

1 (2%)

  

Not Reportable

7 (14%)

Descriptive

total

CCR5-tropic

Dual/Mixed/CXCR4-tropic

Female gender, n (%)

16 (31%)

12 (39%)

4 (31%)

Mean age (SD)

45 (9)

46 (8)

40 (12)

Median time from HIV-1 diagnosis, years (IQR)

17 (14-19)

16 (13-18)

18 (17-22)

Italian nationality, n (%)

48 (94%)

29 (93%)

12 (92%)

Risk Factor, n (%)

Heterosexual

15 (29%)

11 (35%)

3 (23%)

 

Homosexual/Bisexual

17 (33%)

11 (35%)

4 (31%)

 

IDU

14 (27%)

7 (23%)

3 (23%)

 

Other/Unknown

5 (10%)

2 (6%)

3 (23%)

CDC stage, n (%)

A

16 (32%)

11 (35%)

3 (25%)

 

B

10 (20%)

9 (29%)

1 (8%)

 

C

24 (48%)

11 (35%)

8 (67%)

History of mono-dual NRTI therapy, n (%)

37 (72%)

24 (77%)

10 (77%)

Median duration of ART exposure, years (IQR)

14 (11-16)

13 (11-16)

13 (11-15)

No. of drug switches (any change or interruption) experienced (IQR)

13 (9-16)

13 (9-15)

11 (7-15)

Patients previously exposed to drug class, n (%)

NRTI

50 (98%)

31 (100%)

13 (100%)

 

NNRTI

44 (86%)

29 (93%)

10 (77%)

 

Unboosted PI

49 (96%)

30 (97%)

13 (100%)

 

Boosted PI

35 (69%)

22 (71%)

8 (61%)

CD4 count, median cells/mm3 (IQR)

334 (182-535)

387 (214-464)

211 (198-518)

HIV-1 RNA load, median log10 cp/ml (IQR)

3.66 (2.55-4.30)

3.9 (3.6-4.1)

4.2 (4.0-4.8)

CD4 count at nadir, median cells/mm3 (IQR)

64 (18-191)

138 (31-200)

14 (6-41)

HIV-1 RNA load at zenith, median Log10 cp/ml (IQR)

5.3 (4.6-5.7)

5.5 (4.8-5.7)

5.4 (4.5-5.6)